Current Report Filing (8-k)
2018年6月2日 - 5:17AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 1, 2018 (May 27, 2018)
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
File
Number)
|
|
Identification
Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
May 27, 2018,
Raymond F. Akers, Jr.,
submitted
his written resignation (the “Resignation Letter”) from
Akers Biosciences, Inc.’s (the “Company”)
board of directors (the “Board”) effective immediately.
Dr. Akers did
not state in the Resignation Letter that he had any disagreement with the Company. Dr. Akers thereafter delivered a letter, dated
May 30, 2018 (the “Disagreement Letter”), setting forth his disagreements with the Company. A copy of the Resignation
Letter and the Disagreement Letter are attached hereto as Exhibit 17.1 and Exhibit 17.2 respectively.
The
Company believes that Dr. Akers resigned due to his significant differences with other members of the Board regarding the management
of the Company, its accounting and business practices and its counsel.
As
previously disclosed the Company’s audit committee of the Board has been reviewing certain revenue recognition items with
respect to the first quarter of 2018, as well as previous quarters. The Company believes Dr. Akers has not been fully cooperative
in connection with such review.
In
accordance with the requirements of Item 5.02(a) of Current Report on Form 8-K, the Company has provided Dr. Akers with the opportunity
to furnish the Company as promptly as possible with a letter addressed to the Company stating whether he agrees with the statements
made by the Company in response to this Item 5.02 and, if not, stating the respects in which he does not agree.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS BIOSCIENCES, INC.
|
|
|
|
Date:
June 1, 2018
|
By:
|
/s/
John J. Gormally
|
|
|
John
J. Gormally
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 6 2024 まで 7 2024
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Akers Biosciences Inc (ナスダック市場): 0 recent articles
その他のAkers Biosciences, Inc.ニュース記事